CHUSPAN SCS BP Treatment of Churg–Strauss Syndrome Without Poor-Prognosis Factors

The recruitment status of this study is unknown because the information has not been verified recently.

Verified November 2006 by Hospices Civils de Lyon. Recruitment status was Active, not recruiting

First Received on November 13, 2006. No Changes Posted

Sponsor:	Hospices Civils de Lyon
Information provided by:	Hospices Civils de Lyon
ClinicalTrials.gov Identifier:	NCT00399399

Purpose

To assess the efficacy of systemic corticosteroids alone as first-line treatment of Churg–Strauss syndrome without poor-prognosis factors as defined by the five-factor score (FFS=0), and to compare the efficacy and safety of azathioprine vs pulse cyclophosphamide as adjunctive immunosuppressive therapy to treat failure or relapse

Condition	Intervention	Phase
Churg-Strauss Syndrome	Drug: azathioprine Drug: cyclophosphamide	Phase IV

Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	CHUSPAN SCS BP Treatment of Churg–Strauss Syndrome Without Poor-Prognosis Factors: a Prospective Randomized Study in 72 Patients.

Resource links provided by NLM:

MedlinePlus related topics: Vasculitis

Drug Information available for: Cyclophosphamide Azathioprine sodium salt Azathioprine

U.S. FDA Resources

Further study details as provided by Hospices Civils de Lyon:

Primary Outcome Measures:

Number of events (failures, relapses and/or deaths) occurring in each group, defining the disease-free survival rate, measured at study end (mean follow-up of 5 years)

Secondary Outcome Measures:

Overall survival, relapse rate and adverse events, measured at study end (mean follow-up of 5 years)

Estimated Enrollment:	72
Study Start Date:	July 1996

Detailed Description:

All patients initially treated with systemic corticosteroids alone: optional IV methylprednisolone pulse (15 mg/kg) at treatment start followed by oral prednisone (1 mg/kg/day) according to a tapering schedule. Treating physicians allowed to treat minor relapses with corticosteroids without referring the patient for randomization, as long as the prednisone dose did not exceed 0.5 mg/kg for 1 month.

Patients in whom prednisone doses could not be tapered below 20 mg, those who failed to enter remission and those who relapsed were randomized to receive either 6 months of oral azathioprine (2mg/kg/day) or 6 cyclophosphamide pulses (0.6g/m2 D1, D15, D30 then every month)

Eligibility

Ages Eligible for Study:	15 Years to 90 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Men and women with newly diagnosed Churg-Strauss syndrome;
absence of poor prognostic factors as defined by the five-factor score (serum creatinine > 140 μmol/l or 1.58 mg/dl, proteinuria > 1 g/day, severe gastrointestinal tract involvement, specific cardiomyopathy and/or central nervous system involvement;
written informed consent.

Exclusion Criteria:

age < 15 years, previously treated Churg-Strauss syndrome;
history of cancer;
pregnant or breast-feeding women;
psychiatric disorders that might compromise compliance with therapy;
contraindication to study drug;
other ongoing therapeutic trial;
concomitant viral hepatitis B or C or human immunodeficiency virus (HIV) infection

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00399399

Locations

Switzerland
Camillo Ribi
Geneva, Switzerland

Sponsors and Collaborators

Hospices Civils de Lyon

Investigators

Principal Investigator:

Jean-François Cordier, MD

Hospices Civils de Lyon

More Information

Additional Information:

Related Info This link exits the ClinicalTrials.gov site

No publications provided by Hospices Civils de Lyon

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Ribi C, Cohen P, Pagnoux C, Mahr A, Arène JP, Lauque D, Puéchal X, Letellier P, Delaval P, Cordier JF, Guillevin L; French Vasculitis Study Group. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum. 2008 Feb;58(2):586-94.

ClinicalTrials.gov Identifier:	NCT00399399 History of Changes
Other Study ID Numbers:	95.067
Study First Received:	November 13, 2006
Last Updated:	November 13, 2006
Health Authority:	France: Afssaps - French Health Products Safety Agency

Keywords provided by Hospices Civils de Lyon:

Churg-Strauss
Vasculitis
Therapy
Cyclophosphamide
Azathioprine

Additional relevant MeSH terms:

Churg-Strauss Syndrome
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Systemic Vasculitis
Vasculitis
Vascular Diseases
Cardiovascular Diseases
Granuloma
Lymphoproliferative Disorders
Lymphatic Diseases
Autoimmune Diseases
Immune System Diseases
Azathioprine
Cyclophosphamide

Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antimetabolites, Antineoplastic
Antineoplastic Agents
Therapeutic Uses
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Myeloablative Agonists

ClinicalTrials.gov processed this record on February 09, 2012